Sun Pharmaceutical Industries Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Emkay and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: Emkay

Keep track of all breaking news and updates on Sun Pharmaceutical Industries Ltd. from all sources in a single place.

Sun Pharmaceutical Industries Ltd.

14 Apr 2025, 06:48PM

1693.10

-0.70%

Company Update

Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Confirmation Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018

pdf

Sun Pharmaceutical Industries Ltd.

13 Apr 2025

1693.10

-0.70%

Stock downfall: The side effects are real, but Sun Pharma stays on its feet

Business Standard

Growth hormone kicks in as India's largest pharma firm's vital signs hold amid generic strain

Sun Pharmaceutical Industries Ltd.'s price crossed below 50Day SMA today

Sun Pharmaceutical Industries Ltd.

13 Apr 2025

1693.10

-0.70%

Drug makers Glenmark, Sun Pharma, Zydus recall products in US

Business Line

Companies initiate Class-II recall, which happens when use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences

Emkay released a Buy report for Sun Pharmaceutical Industries Ltd. with a price target of 2400.0 on 10 Apr, 2025.

Glenmark, Sun Pharma, Zydus Recall Products In US

NDTV Profit | 13 Apr 2025

Sun Pharmaceutical Industries Ltd.

11 Apr 2025

1693.10

-0.70%

Sun Pharma stock up 2.4% as roads cleared for launch of alopecia drug

Business Standard

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27

Sun Pharmaceutical Industries Ltd. is trading below its 50 day SMA of 1696.3

Here's why Sun Pharma share price advanced 5% in trade on April 11; details

Business Standard | 11 Apr 2025

Sun Pharmaceutical Industries Ltd.

10 Apr 2025

1693.10

-0.70%

US court clears Sun Pharma to launch Leqselvi for alopecia areata treatment

Business Standard

Sun Pharma is now preparing to launch the drug in US markets after facing legal issues since November 2024

Promoters unpledged 0.10% of shares in last quarter. Total pledge stands at 0.69% of promoter holdings

Sun Pharmaceutical Industries Ltd.

10 Apr 2025

1693.10

-0.70%

Sun Pharmasays US appeals court removes injunction on Leqselvilaunch

Business Line

The pharma stock closed 2 per cent lower on Wednesday. Trading operations will resume on April 11.

Sun Pharmaceutical Industries Ltd. is trading below its 50 day SMA of 1696.3

Sun Pharmaceutical Industries Ltd.

10 Apr 2025

1693.10

-0.70%

Company Update

Sun Pharmaceutical Industries Ltd - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And …

BSE India

Intimation of order vacating preliminary injunction on LEQSELVI

pdf

Sun Pharmaceutical Industries Ltd.

10 Apr 2025

1693.10

-0.70%

Order vacating injunction on Leqselvi a material positive

Buy: Sun Pharmaceutical Industr...

Emkay

The US Court of Appeals has vacated the preliminary injunction against Sun Pharma’s launch of Leqselvi which was granted by the US District Court of New Jersey in Nov-24.

Sun Pharmaceutical Industries Ltd. is trading above its 30 day SMA of 1687.0

Sun Pharmaceutical Industries Ltd.

07 Apr 2025

1693.10

-0.70%

Sun Pharma launches Fexuprazan tablets for Erosive Esophagitis treatment

Business Standard

Sun Pharmaceutical Industries on Monday said it has introduced a medication for the treatment of Erosive Esophagitis of all grades. The Mumbai-based drug major, in a statement, said it has launched Fexuprazan tablets (40 mg) in India under the brand name Fexuclue, a novel potassium-competitive acid blocker (PCAB). The product is approved as a new treatment for adults with Erosive Esophagitis of all grades, it added. Sun Pharma has obtained rights from South Korea-based Daewoong Pharmaceutical to manufacture and commercialise the medication in India. As per the agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties, it said. "Erosive Esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. Fexuclue is a best-in-class treatment option with the potential to bridge this gap," Sun Pharma CEO India Business Kirti Ganorkar...